Biotech and Pharmaceuticals Pharmaceuticals

  • Jim Cramer on "Mad Money."

    Jim Cramer explains how China's manufacturing-based economy leaves it vulnerable to U.S. trade tariffs.

  • Investing in cannabis is 'a great hedge' for alcohol and drug companies, Tilray CEO says

    Jim Cramer sits down with Tilray CEO Brendan Kennedy to get his take on the future of medical and recreational marijuana.

  • Cannabis 'a great hedge' for alcohol and drug companies: Tilray CEO

    Jim Cramer sits down with Tilray CEO Brendan Kennedy to get his take on the future of medical and recreational marijuana.

  • Brendan Kennedy, CEO, Tilray 

    Jim Cramer sits down with Tilray CEO Brendan Kennedy to get his take on the future of medical and recreational marijuana.

  • Sept 18- Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira. AbbVie shares fell 2.5 percent to $92.98 on Tuesday afternoon. The case...

  • SAN FRANCISCO— Pharmaceutical giant AbbVie illegally plied doctors with cash, gifts and services to prescribe one of the world's best-selling drugs, Humira, despite its potentially deadly complications, a California official said in a lawsuit filed Tuesday. It's likely patients were prescribed Humira because of the kickbacks provided by AbbVie and not...

  • Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts.

    AbbVie shares fell almost 3 percent on Tuesday following a lawsuit by the California Department of Insurance alleging that the pharmaceutical company gave health-care providers kickbacks to prescribe its arthritis drug Humira.

  • California insurance department sues Abbvie over alleged kickbacks

    CNBC's Meg Tirrell reports on shares of drugmaker Abbvie falling on news of a lawsuit by the California Department of Insurance.

  • Sept 18- Viking Therapeutics Inc's shares more than doubled on Tuesday after its experimental liver disease treatment met the goals of a mid-stage trial by lowering cholesterol and liver fat levels in patients. Successful drugmakers could enter a market worth potentially $30 billion a year. Viking's shares were trading at $25 in premarket trading on...

  • Jim Cramer on Mad Money

    Jim Cramer reveals the big opportunity behind the decline in medical device stocks.

  • Bausch Health CEO Joe Papa talks R&D, company's turnaround

    Jim Cramer sits down with Bausch Health Companies Chairman and CEO Joe Papa, who presents some of his pharmaceutical company's new products and discusses the ongoing turnaround.

  • An employee carries an empty styrofoam box used for transporting human organs into an operation room. 

    It seems like an implausible solution: Accepting a transplant of an organ that is infected with hepatitis C. But, some patients faced with a last resort are doing just that -- accepting infected organs and then starting a course of antiviral drugs to eliminate traces of the virus, USA Today reports. 

  • Justice Department clears Cigna-Express Scripts merger

    CNBC's Leslie Picker reports the Depart of Justice antitrust division has approved the merger between Cigna and Express Scripts.

  • KANSAS CITY, Mo.— The head of a small Kansas City pharmaceutical company is defending himself after a financial publication reported that he said he had a "moral requirement" to raise the price of a 65- year-old antibiotic by 400 percent. Nostrum Laboratories founder Nirmal Mulye said his comments to the London- based Financial Times were taken out of context, The...

  • *Shire gains after China nod to Takeda deal. MILAN, Sept 14- Britain's top share index tracked higher European markets on Friday with the mood buoyed by easing trade worries, while Shire rose after China cleared Takeda's plans to buy the drugmaker. President Donald Trump said on Thursday that the United States was under no pressure to make a trade deal with China,...

  • FRANKFURT/ BENGALURU, Sept 14- European and North American regulators have found a second toxin that may cause cancer in humans in a commonly used blood pressure drug made by Chinese firm Zhejiang Huahai Pharmaceutical Co Ltd.. Health regulators in the European Union, United States and Canada had already recalled drugs made with the company's active...

  • *Purchase approved by U.S., Brazil, China regulators. Sept 14- Takeda Pharmaceutical Co Ltd said on Friday China approved its purchase of Shire Plc, the latest regulator to clear the $62 billion deal and bring the Japanese group closer to becoming a global top 10 drugmaker. The acquisition, which will be the largest overseas purchase by a Japanese company, has...

  • U.S. stocks made solid gains Thursday as Apple and Qualcomm led a rally in technology companies. Drugmakers and health insurers also rose. The Russell 2000 index of smaller-company stocks sank 1.38 points, or 0.1 percent, to 1,714.32.

  • *Roche could have $10 billion sales gap to fill by 2022. LONDON/ ZURICH, Sept 13- Roche, the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Chief Executive Severin Schwan told Reuters he was confident he could fill the sales gap...

  • WASHINGTON, Sept 13- The chairman of the Federal Trade Commission, which stops mergers it believes will push up prices, signaled on Thursday he was willing to consider tougher enforcement, a move that could affect high profile big tech companies but also energy producers, drug makers and a big swath of the U.S. economy. Joseph Simons, who was nominated by President...